Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 336,481
  • Shares Outstanding, K 26,940
  • Annual Sales, $ 2,470 K
  • Annual Income, $ -60,080 K
  • 60-Month Beta N/A
  • Price/Sales 136.07
  • Price/Cash Flow N/A
  • Price/Book 3.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.80
  • Number of Estimates 2
  • High Estimate -0.64
  • Low Estimate -0.96
  • Prior Year -3.07
  • Growth Rate Est. (year over year) +73.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.05 +37.57%
on 04/24/19
12.98 -4.08%
on 05/10/19
+2.83 (+29.42%)
since 04/23/19
3-Month
8.67 +43.60%
on 03/08/19
12.98 -4.08%
on 05/10/19
+2.60 (+26.40%)
since 02/22/19

Most Recent Stories

More News
Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline

Continuing to execute commercial build and launch readiness for Gvoke HypoPen(TM) and Gvoke PFS(TM)

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam

Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris' diazepam

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress

Continuing to execute commercial build and launch readiness for Gvoke HypoPen(TM)

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 12.43 (-0.48%)
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 12.43 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade XERS with:

Business Summary

Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 13.00
1st Resistance Point 12.75
Last Price 12.44
1st Support Level 12.22
2nd Support Level 11.94

See More

52-Week High 27.98
Fibonacci 61.8% 20.60
Fibonacci 50% 18.33
Fibonacci 38.2% 16.05
Last Price 12.44
52-Week Low 8.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar